explore -WSS

explore

author：leisure time 2025-09-30 23:06:00 - browse：564

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

A pill being developed by Danish drugmaker Novo Nordisk may lead to greater weight loss than the obesity therapy Wegovy, the company reported Thursday, citing early data.

In a Phase 1 trial, participants experienced an average of 13.1% weight loss after 12 weeks of taking the experimental oral medicine amycretin, according to data presented at an investor meeting. In comparison, in an earlier Phase 3 trial of the injectable drug Wegovy, people taking Wegovy lost about 6% of their body weight over the same time period.

Novo Nordisk has been on a mission to capitalize on its success with Wegovy, which brought in $4.5 billion in sales last year. (The drug is also sold as a diabetes treatment under the name Ozempic. That version of the drug brought in another $14 billion in sales).

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

WSS

With competition flaring, obesity drug hits goal in liver disease study

Flagship Pioneering startup Sonata Therapeutics lays off 21

He's a Nobel laureate. Critics say he was misleading on Covid

In utero gene editing: an explainer

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Measles policy set amid Florida outbreak alarms vaccine proponents

Wikipedia

explore

entertainment

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

Jerome Adams on the need for new antivirals for Covid

A new drug could help frostbite victims avoid its ravages

Anesthesiologist group: stop taking Ozempic before surgery

Medicare Advantage enrollment hits roughly 33.4 million

Moonlake's readout produced a cash windfall. Risks remain

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

United colonoscopy coverage change 'may cost lives,' doctors say

The Harvard botanist who searched for psychedelics in the Amazon

knowledge

STAT readers on older presidents, polypills, Medicare, and more

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

In 'major milestone,' FDA approves first cell therapy for solid tumors

Ukraine seeks to reclaim its role as a hub for clinical trials

NIH study of ME/CFS points to clear biological hallmarks

hotspot

explore

explore

leisure time